Healing & Repair Research

BPC-157 (Body Protection Compound 157): Pentadecapeptide Research Data

A conservative review of BPC-157 research: the pentadecapeptide from human gastric juice, the NO/VEGF angiogenic mechanism, the Sikiric preclinical body, the five small human studies, and the July 2026 FDA advisory-committee vote.

·
Fact-checked · Reviewed by Remy Research Editorial Board
Update History ▾
October 7, 2026: Corrected the human-data record to five small studies (two abstract-only placebo-controlled enema studies from 2002–2005 and three uncontrolled pilot reports by one Florida physician; the 2025 IV pilot was not the first) and added FDA's July 2026 briefing, which found the one randomised efficacy trial too thinly reported to support effectiveness; fixed the Lee & Burgess and McGuire citations; added the July 23, 2026 advisory-committee vote; corrected the April 2026 regulatory note (FDA lists BPC-157 as nominated but withdrawn, which did not make it compoundable), replaced a non-existent Reuters headline with the April 15, 2026 Reuters report and removed an unsupported "first time" claim; corrected the TB-500 definition (a 7-amino-acid thymosin beta-4 fragment); and replaced the reconstitution section with a format-and-storage note. Dose figures removed.
May 28, 2026: Added the FDA April 2026 regulatory update (BPC-157's Category 2 status) and the July 23–24 2026 PCAC 503A Bulks List review.
May 27, 2026: Initial publication with literature review covering Sikiric et al. preclinical body, Lee & Burgess 2025 first human IV pilot (PMID 40131143), McGuire 2025 narrative review (PMC12446177), and FDA PCAC July 23-24 2026 hearing context.
TL;DR — Research Summary

BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide derived from a stable fragment of a protein originally isolated from human gastric juice, with a deep rodent-model literature on tissue repair and a thin human clinical record. The mechanistic narrative built by Sikiric and colleagues over more than two decades centres on nitric oxide system modulation, VEGF/eNOS-driven angiogenesis, FAK-paxillin growth-factor signalling, and interactions with dopaminergic and serotonergic systems in injury models of tendon, ligament, gastrointestinal mucosa, and vasculature.[1][2] The human record is five small studies: two placebo-controlled enema studies from 2002–2005 reported only as conference abstracts (a 32-person phase 1 safety study and a 53-person ulcerative-colitis trial), and three uncontrolled pilot reports by one Florida physician, the latest a two-subject intravenous safety pilot by Lee and Burgess in 2025.[12][3] No controlled trial has shown efficacy: FDA's July 2026 briefing found the one randomised efficacy trial too thinly reported and exploratory to support effectiveness.[12] The McGuire et al. 2025 narrative review in Current Reviews in Musculoskeletal Medicine concluded that BPC-157 should be considered investigational, with the preclinical signal still outpacing the human evidence base.[4] In July 2026 an FDA advisory committee voted to recommend allowing U.S. compounding pharmacies to use BPC-157 for ulcerative colitis; the vote is non-binding, and no final FDA action has followed.[5]

BPC-157 is not an approved medicine, and material supplied by Remy Research is for in-vitro laboratory research only — not for human or veterinary use.

Compliance note: this page is a research review, not a treatment guide. It does not provide human-use dosing, therapeutic recommendations, or any clinical-use instructions, and should be read in the same non-therapeutic frame required across Remy's research content.

What Is BPC-157?

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a stable fragment of a larger protein originally identified in human gastric juice — "Body Protection Compound" is the descriptor the Sikiric group attached to the parent material based on its experimental gastroprotective behaviour. The synthetic 15-residue sequence used in modern research is what the catalogue refers to as "BPC-157".[1]

Standard chemistry: molecular formula C62H98N16O22, molecular weight 1419.55 g/mol, CAS number 137525-51-0. Free-base and acetate-salt forms both circulate in the literature; the acetate salt is the form most often referenced in compounding-pharmacy filings and the form the FDA's 2026 PCAC docket evaluates alongside the free base.[5]

The peptide's research interest comes from two unrelated properties: it is unusually stable in human gastric juice (the experimental observation that named the parent compound), and its rodent-model phenotype is reproducibly broad — tendon, ligament, gut-mucosal, vascular, and central-nervous-system models all show signals in the Sikiric body of work.[2] Both of those features make it an attractive tool compound. Neither makes it a finished medicine.

Mechanism of Action: Nitric Oxide, Angiogenesis & Growth Factor Modulation

The mechanistic narrative for BPC-157 was assembled across roughly two decades of rodent work, primarily by Sikiric and colleagues at the University of Zagreb, with mechanistic detail added by independent vascular-biology groups. Three pathway clusters anchor it:

Adjacent literature describes interactions with dopaminergic, serotonergic, and GABAergic systems in rodent CNS models, which the Sikiric group has used to argue for a broader stabilising role across multiple injury contexts.[2] No single receptor has been cleanly identified as the BPC-157 target. The honest summary is that the mechanism is multi-pathway and partially resolved, not single-receptor and clean.

BPC-157 at a Glance
PropertyDetail (research-use context)
ClassSynthetic pentadecapeptide (15 amino acids)
SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
OriginStable fragment of "Body Protection Compound" identified in human gastric juice
Reported mechanisms (preclinical)Nitric-oxide pathway, angiogenesis, growth-factor modulation
Evidence basePredominantly rodent and in-vitro models; very limited human data
Regulatory statusNot approved by any regulator — research use only

Preclinical Evidence: Tendon, Ligament, GI, and Vascular Models

The BPC-157 preclinical body is large, mostly rodent, and concentrated in four model families.

1. Tendon and ligament injury

Rat Achilles tendon transection and medial collateral ligament injury models from the Sikiric group and independent orthopaedic labs report accelerated functional recovery, increased tenocyte outgrowth, and earlier reappearance of organised collagen in BPC-157-treated animals compared with vehicle controls. Mechanistically, the FAK-paxillin signal and VEGF-driven micro-vascular ingrowth are the most common explanations offered in those papers.[7]

2. Gastrointestinal mucosa

The original "gastroprotection" framing comes from rodent models of ethanol-induced gastric lesions, cysteamine-induced duodenal ulceration, and short-bowel syndrome. BPC-157 reduced mucosal damage scores and accelerated re-epithelialisation in those models, which is the experimental observation that named the parent material.[1][2]

3. Vascular and ischaemia models

Hsieh et al. and related vascular-biology work showed angiogenic responses in chick chorioallantoic membrane assays, capillary-outgrowth assays, and rodent ischaemic-limb and venous-occlusion models. The recurring observation is faster restoration of perfusion, with VEGFR2 upregulation as the proposed proximal cause.[6]

4. Central nervous system models

A smaller body of rodent CNS work reports interactions with dopaminergic, serotonergic, and GABAergic signalling, with claims around stabilisation in models of haloperidol-induced catalepsy, MPTP-induced parkinsonism, and amphetamine-induced disturbances. This literature is less independently replicated than the gut and vascular work and should be read with corresponding caution.[2]

Across all four families, the model species is almost always rat or mouse, the route is most often intraperitoneal or oral via drinking water, and animal dose ranges do not translate cleanly to a human scale.

Human Data — Five Small Studies

The human record for BPC-157 is five small studies, as listed in FDA's July 2026 briefing for its Pharmacy Compounding Advisory Committee.[12] Two were placebo-controlled studies in which BPC-157 was given by enema, and both were reported only as conference abstracts: a 2002–2003 phase 1 tolerability and pharmacokinetic study in 32 healthy volunteers, 24 of whom received BPC-157, and a 2005 multicentre, randomised, double-blind trial in 53 people with mild-to-moderate ulcerative colitis, 46 of whom completed it.[12]

The other three are uncontrolled pilot reports by one Florida physician. A 2021 retrospective chart review asked 16 patients by phone about knee pain after intra-articular BPC-157, alone or with thymosin beta-4; there was no control group and no validated outcome measure.[9] A 2024 single-arm pilot in 12 women with interstitial cystitis reported self-rated symptom improvement, again without a control arm.[10] And a 2025 intravenous safety pilot by Lee and Burgess in two adults, indexed at PMID 40131143, reported no measurable change in the heart, liver, kidney, thyroid or glucose markers it tested.[3]

None of the pilot reports is an efficacy trial. Two subjects cannot reveal rare adverse events, dose-response or pharmacokinetics, and uncontrolled self-reports cannot separate a drug effect from placebo or natural recovery.[3] The one randomised efficacy trial does not fill that gap: FDA's July 2026 briefing found a lack of evidence that BPC-157 is effective for ulcerative colitis, because interpretation of that single, small trial is limited by the lack of details in its meeting abstract and the exploratory nature of the study.[12]

Read together, the five studies show that BPC-157 has been tested in people on a small scale, not that it works in people. Any source treating them as proof of clinical efficacy is overreading them; any source claiming BPC-157 has no human data at all is mistaken.

2025 Narrative Review: McGuire et al. — Still Investigational

McGuire and colleagues at the University of Utah published a narrative review in Current Reviews in Musculoskeletal Medicine in 2025 (PMC12446177), framing BPC-157 in the orthopaedic-and-recovery context where it is most commonly discussed.[4]

The review summarises the proposed mechanisms — VEGFR2 activation, nitric oxide synthesis through the Akt-eNOS axis, and ERK1/2 signalling — and finds human data extremely limited: only three pilot studies, covering knee pain, interstitial cystitis and intravenous safety. No adverse effects were reported in them, but rigorous, large-scale trials are lacking. The authors conclude that until well-designed clinical trials are run, BPC-157 should be considered investigational and its use approached with caution.[4]

McGuire's count does not include the two earlier placebo-controlled enema studies that FDA's July 2026 briefing also lists, both reported only as conference abstracts.[12] With those included, the reference frame for how a research catalog should describe BPC-157 in 2026 is: real preclinical signal, five small human studies, no controlled trial showing efficacy, no validated human dosing.

Regulatory update — FDA, April & July 2026. FDA's Category 2 page for bulk drug substances that may present significant safety risks, updated April 22, 2026, lists BPC-157 as "nominated but withdrawn" (previously in Category 2, withdrawn by the nominators), and FDA's May 2026 503A category list does not place it in Category 1, so the change did not make it compoundable.[13] A Federal Register notice (April 16, 2026) scheduled a PCAC meeting on July 23–24, 2026 to consider BPC-157 for inclusion on the 503A Bulks List.[8] TB-500, KPV, and MOTS-c are on the same docket (Docket FDA-2025-N-6895). On July 23, 2026 the committee voted to recommend adding BPC-157 to the 503A Bulks List for ulcerative colitis, reportedly 8 to 6 with one abstention, against the advice of FDA's own reviewers.[11] The vote is non-binding, and no final FDA action had been published as of October 7, 2026. This is a U.S. regulatory question; research-use supply is not affected by it. Sources: reuters.com; FDA PCAC meeting notice.

Research Format & Storage

For research use, BPC-157 ships as a lyophilized powder in a sealed vial. The handling notes below describe the format only:

None of this is human-use guidance. Wider storage questions are covered in the peptide stability and storage guide.

What the BPC-157 Literature Does Not Yet Give You

Cautious reading of BPC-157 requires acknowledging four real gaps.

These gaps are not arguments against studying BPC-157. They are arguments against overselling it.

BPC-157 Research-Use Supply & Format

For research use, BPC-157 belongs in the category of preclinical repair-signalling research peptides — typically supplied as a 10 mg lyophilized vial with cold-chain handling, with the active lot reference confirmed before dispatch. The catalog format mirrors how investigators have used the peptide in the published animal-model literature, with no human-use framing attached.

The BPC-157 10mg research vial page documents the lyophilised format, while the separate BPC-157 20mg research pen keeps its own prefilled format, reference price, stock status, and evidence boundary. Researchers comparing BPC-157 with thymosin beta-4 / TB-500 can also review the BPC-157 + TB-500 blend vial; the rationale for the blend format sits in the sister review at TB-500 (Thymosin Beta-4) actin and healing research. Published Janoshik COAs across the Retatrutide range are indexed in the COA library, and Dubai sourcing checks are in the BPC-157 Dubai guide.

Adjacent reading on this site: the KPV tripeptide review covers the closest small-peptide anti-inflammatory comparator with similar PCAC-docket exposure, and the GHK-Cu copper peptide review covers the most-studied short repair-signalling peptide in the dermal extracellular-matrix lane. None of those three molecules is an approved therapeutic; each is supplied strictly for in-vitro research use only.

Our Research Standards

This article prioritizes primary preclinical literature, peer-reviewed reviews, and the public FDA docket. Where the human clinical record is thin or absent, we say so directly. No therapeutic, human-use, or veterinary-use claim is made here. Read our editorial policy →

RP
Editorial Reviews

Research Library, Remy Research

The Remy Research editorial board reviews peptide chemistry, preclinical literature, and regulatory developments across the research-use catalog. The board's standing brief is to keep article framing inside what the published evidence supports, with explicit flags where the literature is preclinical, anecdotal, or pending agency review.

About the editorial team →

BPC-157 Research FAQ

What is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a stable fragment of a larger protein originally isolated from human gastric juice. CAS number 137525-51-0, molecular formula C62H98N16O22, molecular weight 1419.55 g/mol. It is studied as a preclinical research peptide and is not an approved medicine in any major jurisdiction.[1]

What is BPC-157's proposed mechanism of action?

The most-cited mechanistic narrative for BPC-157 centres on nitric oxide (NO) system modulation, VEGF/eNOS-driven angiogenesis, and growth-factor signalling through the FAK-paxillin pathway. Animal-model work from the Sikiric group also reports interactions with the dopaminergic, serotonergic, and GABAergic systems. Receptor-level mechanism is not fully resolved, and most data come from rodent injury models rather than human pharmacology.[2][6]

Is there any human clinical evidence for BPC-157?

Only five small studies: two placebo-controlled enema studies from 2002–2005 reported only as conference abstracts (a 32-person phase 1 safety study and a 53-person ulcerative-colitis trial), and three uncontrolled pilot reports by one Florida physician — a 2021 knee-pain chart review, a 2024 pilot in 12 women with interstitial cystitis, and a 2025 two-person intravenous safety pilot by Lee and Burgess (PMID 40131143). No controlled trial has shown efficacy: the only randomised efficacy trial (2005, reported only as a conference abstract) was judged by FDA in 2026 to be too thinly reported and exploratory to support effectiveness. The McGuire et al. 2025 narrative review in Current Reviews in Musculoskeletal Medicine concluded that BPC-157 should be considered investigational despite the preclinical signal.[12][9][10][3][4]

What did the FDA decide about BPC-157 in 2026?

BPC-157 is not FDA-approved. On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding BPC-157 to the 503A Bulks List for ulcerative colitis, reportedly 8 to 6 with one abstention, against the advice of FDA's own reviewers (Docket FDA-2025-N-6895). The vote is non-binding, and no final FDA action had been published as of October 7, 2026. Research-use supply is not affected by the U.S. decision.[5][11]

How does BPC-157 differ from TB-500 (thymosin beta-4)?

BPC-157 is a 15-amino-acid pentadecapeptide derived from a human gastric-juice protein and is studied primarily through nitric oxide, VEGF angiogenesis, and growth-factor pathways. TB-500 is defined by FDA as Ac-LKKTETQ, a 7-amino-acid fragment of the 43-residue actin-sequestering protein thymosin beta-4 (residues 17–23, 889 g/mol); products sold under the name vary, and some contain or claim full-length thymosin beta-4 (about 4,963 g/mol), so a vial's COA mass is what identifies its contents. Its preclinical rationale draws on thymosin beta-4 research into actin cytoskeleton dynamics, cell migration, and tissue repair. Researchers occasionally co-administer them in animal models; that is the rationale behind the BPC-157 + TB-500 blend research vial format. Neither peptide is an approved therapeutic.[14]

How is BPC-157 stored for research?

Lyophilized BPC-157 is stored at 2-8 degrees Celsius, protected from light, and frozen for longer storage; repeated temperature cycling should be avoided. In warm climates, insulated cold-chain shipping helps preserve the peptide in transit.

How should BPC-157 be handled for research use?

BPC-157 is supplied strictly as a lyophilized research peptide for in-vitro laboratory use only. It is not framed for human use, veterinary use, dosing, or therapeutic application. BPC-157 is supplied to a >99% HPLC line standard for in-vitro research; published Janoshik COAs across the Retatrutide range are indexed in the COA library. The active lot reference can be confirmed before dispatch.

What benefits has BPC-157 shown in research models?

In preclinical research, BPC-157 has been studied across four rodent-model families: tendon and ligament injury, gastrointestinal mucosal damage, vascular and ischaemia models, and central-nervous-system models. In those animal studies it is associated with accelerated functional recovery, increased angiogenesis, and reduced mucosal damage scores versus vehicle controls, with the VEGF/eNOS angiogenic axis and FAK-paxillin growth-factor signalling offered as the proposed explanations. These are observations in research models, not validated human benefits: the human record is five small studies, no controlled trial has shown efficacy, and the 2025 McGuire narrative review classifies BPC-157 as still investigational.

What side effects or safety signals does the BPC-157 research record report?

The published human safety record for BPC-157 is five small studies: two placebo-controlled enema studies from 2002–2005 reported only as conference abstracts, and three uncontrolled pilot reports by one Florida physician, including a two-subject intravenous pilot (Lee and Burgess 2025) that reported no measurable change in the markers it tested (PMID 40131143) — far too small to characterise rare adverse events, dose-response, or pharmacokinetics. The controlled data, including a phase 1 pharmacokinetic study, exist only as conference abstracts, so a human side-effect profile is not yet established. This is a research-record summary, not human-safety guidance, and BPC-157 is supplied for in-vitro laboratory use only.

Is there a validated BPC-157 dosage, and does it come in capsules?

No. There is no validated human BPC-157 dosage: published animal work used wide dose ranges in rats and mice that do not translate cleanly to a human scale, and no controlled human trial has shown efficacy. The research format is a 10 mg lyophilized vial for in-vitro work — not a capsule, tablet, or oral consumer product. Any source publishing a specific human BPC-157 protocol is going beyond the published data.

Sources

  1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. doi: 10.2174/138161211796196954 · PMID: 21548867 ↩
  2. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. doi: 10.2174/1570159X13666160502153022 · PMID: 27138887 ↩
  3. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PMID: 40131143 ↩
  4. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi: 10.1007/s12178-025-09990-7 · PMC: PMC12446177 ↩
  5. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — agenda and docket FDA-2025-N-6895. fda.gov advisory committee calendar ↩
  6. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi: 10.1007/s00109-016-1488-y · PMID: 27847966 ↩
  7. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi: 10.1152/japplphysiol.00945.2010 · PMID: 21030672 ↩
  8. Reuters. US FDA to convene expert panel to review wider access to some peptides. April 15, 2026. reuters.com. Federal Register notice 2026-07361, April 16 2026 (PCAC July 23–24 2026 meeting). ↩
  9. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435 ↩
  10. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID: 39325560 ↩
  11. Choi J. FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists. The Hill. July 23, 2026. thehill.com ↩
  12. U.S. Food and Drug Administration. FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate). Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. fda.gov ↩
  13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2; "Bulk drug substances nominated but withdrawn"). Updated April 22, 2026. fda.gov. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (503A categories list). Updated May 14, 2026. fda.gov ↩
  14. U.S. Food and Drug Administration. FDA Briefing Document: TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate). Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. fda.gov ↩

For product-format details, see the BPC-157 10mg research vial and the BPC-157 + TB-500 blend. For the evidence split between the two repair-signalling lanes, read the BPC-157 vs TB-500 research comparison. For handling and compliance context, continue to the BPC-157 Dubai guide and the COA library.

Related Research

Cluster Hub Healing & Recovery Peptides→ Compare KPV vs BPC-157 vs GHK-Cu→ Catalog BPC-157 10mg Research Vial→ Catalog BPC-157 + TB-500 Blend Vial→ Compare BPC-157 vs TB-500 Research Comparison→ Comparison TB-500 (Thymosin Beta-4) Research→ Comparison KPV (Lys-Pro-Val) Tripeptide Research→ Comparison GHK-Cu Copper Peptide Research→ Dubai Guide BPC-157 Dubai: Research Vial, Evidence and COA Guide→ Catalog Research Peptide Catalog — COA-Verified Formats → Literature BPC-157 Dosage: Routes, Ranges & the Human-Data Gap →